Michelle E. Melisko

MD

Breast oncologist

About me

Dr. Michelle E. Melisko is a cancer specialist with expertise in caring for patients with breast cancer.

Also active in research, Melisko is interested in evaluating new chemotherapy combinations, biological therapies and immunotherapies for breast cancer, with a particular focus on treating cancer that has spread to the brain. To foster more rapid advances in breast cancer treatment, she educates patients on clinical trials and encourages them to participate when appropriate.

Melisko earned her medical degree at the Wake Forest School of Medicine and completed a residency in internal medicine at Stanford Medicine. She completed a fellowship in hematology and oncology at UCSF.

  • Education

    Wake Forest University School of Medicine, 1997

  • Residencies

    Stanford Hospital and Clinics, Internal Medicine, 2000

  • Fellowship

    UCSF Medical Center, Hematology/Oncology, 2003

  • Board Certifications

    Hospice & Palliative Medicine, American Board of Internal Medicine

  • Academic Title

    Professor

Carol Franc Buck Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

Decorative Caduceus

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from ...

Recruiting

Decorative Caduceus

Neratinib HER Mutation Basket Study (SUMMIT)

This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-pos...

Recruiting

Decorative Caduceus

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast...

Recruiting

Decorative Caduceus

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patien...

This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previousl...

Recruiting

Decorative Caduceus

Olaparib In Metastatic Breast Cancer

This research study is for patients with metastatic breast cancer. - Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gen...

Recruiting

Share